Kawasaki Disease: Update on Diagnosis, Treatment, and a Still Controversial Etiology

References

• Kawasaki T. Acute febrile mucocutaneous syndrome: clinical observation of 50 cases. Jpn J Allergy. 1967; 16: 178–222
   PubMedGoogle Scholar
• Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974; 54: 271–276
   PubMed Web of Science ®Google Scholar
• Leung D Y. Kawasaki disease. Curt Opin Rheumatol. 1993; 5: 41–50
   PubMedGoogle Scholar
• Dajani A S, Taubert K A, Gerber M A. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993; 87: 1776–1780
   PubMed Web of Science ®Google Scholar
• Burns J C, Matsubara T. Kawasaki disease: recent advances. Trend Cardiovasc Med. 1995; 5: 3–7
   Google Scholar
• Kawasaki T. Kawasaki disease. Acta Paediatr. 1995; 84: 713–715
   Google Scholar
• Fischer P, Gaedicke G. 7S-Immunglobulintherapie beim Kawasaki-Syndrom. Imtnunmodulatorische Therapie mil Immunglobulinen bei Infektionen und Autoimmunerkrankungen, S Zierz, G Langner, WP Nass. Universitätsverlag, Jena 1995; 162–175
   Google Scholar
• Kawasaki disease. Proceedings of the 5th International Kawasaki Disease Symposium, FukuokaJapan, May 22–25, 1995, H Kato. Elsevier, Amsterdam 1995
   Google Scholar
• Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn. 1991; 41: 785–797
   PubMedGoogle Scholar
• Dajani A S, Taubert K A, Takahashi M. Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1994; 89: 916–922
   PubMed Web of Science ®Google Scholar
• Levin E R. Mechanisms of disease-endothelins. N Engl J Med. 1995; 333: 356–363
   PubMed Web of Science ®Google Scholar
• Nash M C, Shah V, Dillon M J. Soluble cell adhesion molecules and von Willebrand factor in children with Kawasaki disease. Clin Exp Immunol. 1995; 101: 13–17
   PubMed Web of Science ®Google Scholar
• Morise T, Takeuchi Y, Takeda R, Karayalcin U, Yachie A, Miyawaki T. Increased plasma endothelin levels in Kawasaki disease: a possible marker for Kawasaki disease. Angiology 1993; 44: 719–723
   Google Scholar
• Mayatepek E, Lehmann W D. Increased generation of cysteinyl leukotrienes in Kawasaki disease. Arch Dis Child. 1995; 72: 526–527
   Google Scholar
• Blum Hoffmann E, Hoffmann G F, Wessel A, Gahr M. Kawasaki syndrome. Association with exposure to carpet shampoo and successful therapy with immunoglobulins in the second week of the illness [in German]. Monatsschr Kinderheilkd. 1992; 140: 273–276
   Google Scholar
• Rauch A M, Glode M P, Wiggins J WJ. Outbreak of Kawasaki syndrome in Denver, Colorado: association with rug and carpet cleaning. Pediatrics 1991; 87: 663–669
   PubMed Web of Science ®Google Scholar
• Kotzin B L, Leung D Y, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol. 1993; 54: 99–166
   PubMed Web of Science ®Google Scholar
• Nigro G, Zerbini M, Krzysztofiak A. Active or recent parvovirus B19 infection in children with Kawasaki disease. Lancet. 1994; 343: 1260–1261
   PubMed Web of Science ®Google Scholar
• Pietra B A, De Inocencio J, Giannini E H, Hirsch R. TCR V beta family repertoire and T cell activation markers in Kawasaki disease. J Immunol. 1994; 153: 1881–1888
   PubMed Web of Science ®Google Scholar
• Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H. Epidemiologic pictures of Kawasaki disease in Japan from the nationwide incidence survey in 1991 and 1992. Pediatrics 1995; 95: 475–479
   PubMed Web of Science ®Google Scholar
• Sakaguchi M, Kato H, Nishiyori A, Sagawa K, Itoh K. Characterization of CD4(+) T helper cells in patients with Kawasaki disease (KD): preferential production of tumour necrosis factor-alpha (TNF-alpha) by V beta 2(-) or V beta 8(-) CD4(+) T helper cells. Clin Exp Immunol. 1995; 99: 276–282
   PubMed Web of Science ®Google Scholar
• Abe J, Kotzin B L, Meissner C. Characterization of T cell repertoire changes in acute Kawasaki disease. J Exp Med. 1993; 177: 791–796
   PubMed Web of Science ®Google Scholar
• Curtis N, Zheng R, Lamb J R, Levin M. Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Child. 1995; 72: 308–311
   PubMed Web of Science ®Google Scholar
• Leung D YM, Giorno R C, Kazemi L V, Flynn P A, Busse J B. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunol. 1995; 155: 5018–5021
   PubMed Web of Science ®Google Scholar
• Abe J, Kotzin B L, Jujo K. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci USA. 1992; 89: 4066–4070
   PubMed Web of Science ®Google Scholar
• Curtis N, Chan B, Levin M. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome [letter]. Lancet. 1994; 343: 299
   Google Scholar
• Leung D Y, Meissner H C, Fulton D R, Murray D L, Kotzin B L, Schlievert P M. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet. 1993; 342: 1385–1388
   PubMed Web of Science ®Google Scholar
• Dadaglio G, Garcia S, Montagnier L, Gougeon M L. Selective anergy of V beta 8(+) T cells in human immunodeficiency virus-infected individuals. J Exp Med. 1994; 179: 413–424
   Google Scholar
• Schmid S L, Jackson M R. Making class 11 presentable. Nature 1994; 369: 103–104
   Google Scholar
• Rammensee H G. Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol. 1995; 7: 85–96
   PubMed Web of Science ®Google Scholar
• Lando P A, Dohlsten M, Hedlund G, Brodin T, Sansom D, Kalland T. Costimulation with B7 and targeted superantigen is required for MHC class II-independent T-cell proliferation but not cytotoxicity. Immunology 1993; 80: 236–241
   Google Scholar
• Acharya K R, Passalacqua E F, Jones E Y. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Nature 1994; 367: 94–97
   PubMedGoogle Scholar
• Jardetzky T S, Brown J H, Gorga J C. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994; 368: 711–718
   PubMed Web of Science ®Google Scholar
• Kim J S, Urban R G, Strominger J L, Wiley D C. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DRI. Science 1994; 266: 1870–1874
   PubMed Web of Science ®Google Scholar
• Vonbonin A, Ehrlich S, Malcherek G, Fleischer B. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-I. Eur J Immunol. 1995; 25: 2894–2898
   PubMed Web of Science ®Google Scholar
• Wen R R, Blackman M A, Woodland D L. Variable influence of MHC polymorphism on the recognition of bacterial superantigens by T cells. J Immunol. 1995; 155: 1884–1892
   Google Scholar
• Wucherpfennig K W, Strominger J L. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases. J Exp Med. 1995; 181: 1597–1601
   PubMed Web of Science ®Google Scholar
• Terai M, Miwa K, Williams T. The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J Infect Dis. 1995; 172: 558–561
   Google Scholar
• Todome Y, Ohkuni H, Mizuse M. Superantigenic exotoxin production by isolates of Staphylococcus aureusfrom the Kawasaki syndrome patients and age-matched control children. J Med Microbiol. 1995; 42: 91–95
   Google Scholar
• Nishiyori A, Sakaguchi M, Kato H, Igarashi H, Miwa K. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome [letter]. Lancet. 1994; 343: 299–300
   Google Scholar
• Leung D YM, Meissner C, Fulton D, Schlievert P M. The potential role of bacterial superantigens in the pathogenesis of Kawasaki syndrome. J Clin Immunol. 1995; 15: S11–S17
   Google Scholar
• Shulman S T. Recommendations for intravenous immunoglobulin therapy of Kawasaki disease. Pediatr Infect Dis J. 1992; 11: 985–986
   Google Scholar
• Newburger J W, Takahashi M, Beiser A S. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991; 324: 1633–1639
   PubMed Web of Science ®Google Scholar
• Yanagawa H, Yashiro M, Nakamura Y, Sakata K, Kawasaki T. Iv gamma globulin treatment of Kawasaki disease in Japan: results of a nationwide survey. Acta Paediatr. 1995; 84: 765–768
   Google Scholar
• Drucker N A, Colan S D, Lewis A B. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89: 252–257
   PubMed Web of Science ®Google Scholar
• Hsu C H, Chen M R, Hwang F Y, Kao H A, Hung H Y. Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome. Pediatr Infect Dis J. 1993; 12: 509–512
   Google Scholar
• Klassen T P, Rowe P C, Gafni A. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome. J Pediatr. 1993; 122: 538–542
   Google Scholar
• Mitterer M, Pescosta N, Vogetseder W, Mair M, Coser P. Two episodes of aseptic meningitis during intravenous immunoglobulin therapy of idiopathic thrombocytopenic purpura [letter]. Ann Hematol. 1993; 67: 151–152
   PubMed Web of Science ®Google Scholar
• Barbolla L, Nieto S, Llamas P. Severe immune haemolytic anaemia caused by intravenous immunoglobulin anti-D in the treatment of autoimmune thrombocytopenia [letter]. Vox Sang. 1993; 64: 184–185
   Google Scholar
• Kressebuch H, Schaad U B, Hirt A, Bianchetti M G. Cerebrospinal fluid inflammation induced by intravenous immunoglobulins. Pediatr Infect Dis J. 1992; 11: 894–895
   PubMed Web of Science ®Google Scholar
• Duhem C, Dicato M A, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol. 1994; 97: 79–83
   PubMed Web of Science ®Google Scholar
• Gaedicke G. Klinik und Therapie der Immunthrombozytopenien des Kindesalters. Sandoz Schriftenreihe, Nuremberg 1990; 1
   Google Scholar
• Blanchette V S, Luke B, Andrew M. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr. 1993; 123: 989–995
   PubMed Web of Science ®Google Scholar
• Gaedicke G. Childhood autoimmune thrombocytopenia: to treat or not to treat. Thrombocytopenia in Childhood, AH Sutor, K. Thomas. Schattauer Verlag, Stuttgart 1994; 129–139
   Google Scholar
• Gaedicke G. Thrombozytopenien im Kindesalter. Pädiatrische Hämatologie. Bücherei des Pädiaters, E Kleihauer, AE Kulozik. Enke Verlag, Stuttgart 1994; 100–109
   Google Scholar
• Imholz B, Imbach P, Baumgartner C. Intravenous immunoglobulin (i.v. IgG) for previously treated acute or for chronic idiopathic thrombocytopenic purpura (ITP) in childhood: a prospective multicenter study. Blut. 1988; 56: 63–68
   PubMedGoogle Scholar
• Imbach P, Wagner H P, Berchtold W. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet. 1985; 2: 464–468
   PubMed Web of Science ®Google Scholar
• Comenzo R L, Malachowski M E, Meissner H C, Fulton D R, Berkman E M. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr. 1992; 120: 926–928
   Google Scholar
• Nugent D J. IVIG in the treatment of children with acute and chronic idiopathic thrombocytopenic purpura and the autoimmune cytopenias. Clin Rev Allergy. 1992; 10: 59–71
   PubMedGoogle Scholar
• Schwartz S A. Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders. J Clin Immunol. 1990; 10: 81–89
   Google Scholar
• Dwyer J M. Manipulating the immune system with immune globulin. N Engl J Med. 1992; 326: 107–116
   PubMed Web of Science ®Google Scholar
• Debre M, Bonnet M C, Fridman W H. Infusions of Fc-gamma fragments for treatment of children with acute immune thrombocytopenic purpura. First International Workshop on: “Platelets, Endothelial Cells: From Autoimmunity to Immunomodulation.”. Foundation Marcel Merieux, Veyrier-du-Lac 1993; 78
   Google Scholar
• Bjorkholm M. Intravenous immunoglobulin treatment in cytopenic haematological disorders. J Intern Med. 1993; 234: 119–126
   PubMed Web of Science ®Google Scholar
• Blanchette V S, Kirby M A, Turner C. Role of intravenous immunoglobulin G in autoimmune hematologic disorders. Semin Hematol. 1992; 29: 72–82
   PubMed Web of Science ®Google Scholar
• Jerne N K. Towards a network theory of the immune system. Ann Immunol (Paris) 1974; 125C: 373–389
   PubMedGoogle Scholar
• Berchtold P, Dale G L, Tani P, McMillan R. Inhibition of autoantibody binding to platelet glycoprotein Ilb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood. 1989; 74: 2414–2417
   PubMed Web of Science ®Google Scholar
• Imbach P. Immune thrombocytopenic purpura and intravenous immunoglobulin. Cancer 1991; 68: 1422–1425
   Google Scholar
• Chen P P, Carson D A, Fischer P. Molecular genetics of human autoantibodies. Pathol Biol. 1994; 42: 798–800
   Google Scholar
• Fischer P, Gaedicke G. Molekulare Immunologie: Neue Konzepte zur Ätiologie und Therapie von Autoimmunerkrankungen in der Padiatrie. Jahrbuch der Kinderhetlkunde 1995, G Gaedicke. Biermann, Ziilpich 1995; 81–99
   Google Scholar
• Dietrich G, Algiman M, Sultan Y, Nydegger U E, Kazatchkine M D. Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood. 1992; 79: 2946–2951
   Google Scholar
• Coutinho A. The network theory: 21 years later. Scand J Immunol. 1995; 42: 3–8
   Google Scholar
• Coutinho A. Beyond clonal selection and network. Immunol Rev. 1989; 110: 63–87
   PubMed Web of Science ®Google Scholar
• Dietrich G, Kaveri S V, Kazatchkine M D. A V region-connected autoreactive subfraction of normal human serum immunoglobulin G. Eur J Immunol. 1992; 22: 1701–1706
   Google Scholar
• Kazatchkine M D, Coutinho A. Clonal taxonomy versus network physiology-are lymphocytes concerned with our definition of idiotypes. Immunol Today 1993; 14: 513–515
   PubMedGoogle Scholar
• Huang D F, Olee T, Masuho Y, Matsumoto Y, Carson D A, Chen P P. Sequence analyses of three immunoglobulin G anti-virus antibodies reveal their utilization of autoantibody-related immunoglobulin Vh genes, but not V lambda genes. J Clin Invest. 1992; 90: 2197–2208
   PubMed Web of Science ®Google Scholar
• Ruiz de Souza V, Kaveri S V, Kazatchkine M D. Intravenous immunoglobulin (IVIg) in the treatment of autoimmune and inflammatory diseases. Clin Exp Rheumatol. 1993; 11: S33–S36, Suppl 9
   PubMedGoogle Scholar
• Ronda N, Kaveri S V, Kazatchkine M D. Treatment of autoimmune diseases with normal immunoglobulin through manipulation of the idiotypic network. Clin Exp Immunol. 1993; 93: 14–15, Suppl 1
   Google Scholar
• Ronda N, Hurez V, Kazatchkine M D. Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox Sang. 1993; 64: 65–72
   Google Scholar
• Dietrich G, Kaveri S V, Kazatchkine M D. Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. Clin Immunol Immunopathol. 1992; 62: S73–S81
   Google Scholar
• Clinical Applications of Intravenous Immunoglobulin Therapy, PL Yap. Churchill Livingstone, Edinburgh 1992.
   Google Scholar
• Infectious Diseases and Immunization Committee CP. Intravenous immune globulin use in children. Can Med Assoc J. 1992; 146: 121–124
   Google Scholar
• Gerst T. Intravenöse Immunglobuline. Sicherheitsaspekte in der Retrospektive. Dtsch. Ärzteblatt. 1995; 92: A1588–1591
   Google Scholar
• Becker H, Mitropoulou G, Helmke K. Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin. Klin Wochenschr. 1989; 67: 286–290
   PubMedGoogle Scholar
• Pogliani E M, Delia Volpe A, Casaroli I, Maffe P F, Corneo G. Lymphocyte subsets in patients with idiopathic thrombocytopenic purpura during high-dose gamma globulin therapy. Allergol Immunopathol Madr. 1991; 19: 113–116
   Google Scholar
• Takei S, Arora Y K, Walker S M. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest. 1993; 91: 602–607
   PubMed Web of Science ®Google Scholar
• Lekova E S, Joffe J, Glode M P. Antigenic recognition by intravenous gamma-globulin of selected bacteria isolated from throats of patients with Kawasaki syndrome. Pediatr Infect Dis J. 1990; 9: 620–623
   Google Scholar
• Hord J D, Grossman N J. Intravenous corticosteroids versus intravenous gammaglobulin in the treatment of acute immune thrombocytopenic purpura. Pediatr Hematol Oncol. 1993; 10: 323–327
   PubMed Web of Science ®Google Scholar
• Pladys P, Bergeron C, Betremieux P, Goasguen J, Fremond B, Le Gall E. [Auto-immune idiopathic thrombocytopenic purpura in children. Apropos of 100 cases.]. Pediatrie. 1993; 48: 181–188
   Google Scholar
• Todd A A, Yap P L. Applications of intravenous immunoglobulin in haematology. Blood Rev. 1992; 6: 105–117
   Google Scholar
• Breiding F, Diibel S, Seehaus T, Klewinghaus I, Little M. A surface expression vector for antibody screening. Gene. 1991; 104: 147–153
   Google Scholar
• McCafferty J, Griffiths A D, Winter G, Chiswell D J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348: 552–554
   PubMed Web of Science ®Google Scholar
• Barbas CF, III, Kang A S, Lerner R A, Benkovic S J. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci USA. 1991; 88: 7978–7982
   PubMed Web of Science ®Google Scholar
• Fischer P, Leu S JC, Yang Y Y, Chen P P. Rapid simultaneous screening for DNA integrity and antigen specificity of clones selected by phage display. Biotechniques. 1994; 16: 828–830
   Google Scholar
• Duchosal M A, Eming S A, Fischer P. Immunization of hu-PBL-SCID mice and the rescue of human monoclonal Fab fragments through combinatorial libraries. Nature 1992; 355: 258–262
   PubMed Web of Science ®Google Scholar
• Duchosal M A, Eming S A, Fischer P. Use of immunized hu-PBL-SCID mice and repertoire cloning to generate specific human monoclonal Fab fragments. Vaccines 92: Modern Approaches to New Vaccines Including Prevention of AIDS, F Brown, RM Chanock, HS Ginsberg, RA Lerner. CSHL Press, Cold Spring Harbor, NY 1992; 19–24
   Google Scholar
• Plückthun A. Mono- and bivalent antibody fragments produced in Escherichia coli: engineering, folding and antigen binding. Immunol Rev. 1992; 130: 151–188
   PubMed Web of Science ®Google Scholar
• Ma J KC, Hiatt A, Hein M. Generation and assembly of secretory antibodies in plants. Science 1995; 268: 716–719
   PubMed Web of Science ®Google Scholar
• Wen R, Cole G A, Surman S, Blackman M A, Woodland D L. Major histocompatibility complex class II-associated peptides control the presentation of bacterial superantigens to T cells. J Exp Med. 1996; 183: 1083–1092
   PubMed Web of Science ®Google Scholar